Alexandria Real Estate Equities, Inc. Strategically Partners With Lilly on Newest Lilly Gateway Labs at the One Alexandria Square Megacampus in San Diego's Torrey Pines to Accelerate the Development of Life-Changing Medicines

Rhea-AI Summary

Alexandria Real Estate Equities (NYSE:ARE) has announced the opening of Lilly Gateway Labs San Diego at their One Alexandria Square Megacampus in Torrey Pines. This strategic partnership with Eli Lilly and Company represents an expansion of the Gateway Labs platform, which has already fostered the development of over 50 novel therapeutics across its existing locations.

The new facility combines ARE's real estate infrastructure and operations expertise with Lilly's scientific resources, mentorship, and venture capital network. Located in a LEED Gold certified all-electric laboratory facility, the hub features modular labs, collaboration spaces, and advanced scientific equipment. Initial tenants include venture-backed biotech companies focusing on Alzheimer's, Parkinson's, cardiovascular diseases, and oncology research.

Insights

Real Estate Investment Trust (REIT) Analyst

Alexandria's partnership with Lilly enhances its biotech ecosystem value proposition while strengthening recurring revenue potential from high-quality life science tenants.

Alexandria Real Estate Equities has strategically expanded its collaboration with pharmaceutical giant Eli Lilly through the opening of Lilly Gateway Labs at the One Alexandria Square Megacampus in San Diego's premium Torrey Pines submarket. This represents a significant enhancement to Alexandria's tenant offering and demonstrates the company's continued ability to attract and retain high-value life science partnerships.

The strategic value of this deal lies in how it reinforces Alexandria's ecosystem-building approach. By integrating world-class real estate infrastructure with Lilly's scientific expertise and capital access, Alexandria strengthens its competitive moat in the specialized life science real estate sector. The Gateway Labs model has already demonstrated success with over 50 therapeutics in development at existing locations, suggesting this expansion could drive meaningful innovation activity at the San Diego campus.

From a real estate perspective, this partnership enhances the value proposition of the One Alexandria Square Megacampus, potentially increasing occupancy rates and rental premiums. Alexandria's long-term investment in the Torrey Pines submarket, dating back to its first acquisition in 1994, positions it to leverage the proximity to renowned research institutions like Salk Institute and UC San Diego - creating a network effect that attracts additional high-quality tenants.

The addition of amenities including café spaces, restaurants, event venues, and meeting facilities further demonstrates Alexandria's focus on creating environments that help tenants attract and retain scientific talent - a crucial competitive advantage in the tight life science labor market. The LEED Gold certification of the facility also aligns with increasing tenant demands for sustainable real estate options.

PASADENA, Calif., Sept. 26, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator, and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, today announced the opening of Lilly Gateway Labs San Diego, powered by Alexandria, on the One Alexandria Square Megacampus in Torrey Pines. First launched by Eli Lilly and Company in 2019 in the San Francisco Bay Area, Lilly Gateway Labs is a shared innovation hub designed to empower biotechnology companies to develop life-changing medicines.

The new Lilly Gateway Labs in San Diego is operated in a strategic collaboration with Alexandria, uniquely integrating Alexandria's world-class real estate infrastructure, facilities and laboratory operations, and placemaking acumen with Lilly's leading scientific expertise, resources, mentorship, and access to capital through its venture network, which includes Alexandria Venture Investments. Building upon Gateway Labs' first three U.S. sites — all established within Alexandria facilities in South San Francisco and Boston — where there are over 50 novel therapeutics and platforms currently in development, Gateway Labs San Diego enhances the ability of its resident companies to bring transformative treatments to patients worldwide.

"We value our nearly two-decade strategic relationship with Lilly, and we are honored to serve as an essential partner to expand the transformative Gateway Labs platform in San Diego," said Hallie E. Kuhn, PhD, senior vice president and co-lead of life science and capital markets at Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "Our partnership embodies our shared mission to accelerate the trajectory of disruptive early-stage biotech companies and foster critical collaboration between innovative biotechs and large pharma. The unique Gateway Labs model is an important engine for biomedical innovation that will deliver lifesaving medicines to patients in the future, and with over 90% of diseases lacking approved medicines, it remains critical that we continue to advance bold science."

Alexandria has been at the vanguard of the development, transformation, and expansion of the San Diego life science ecosystem into one of the world's most innovative clusters since acquiring its first property and pioneering life science real estate in 1994. The site of that foundational acquisition in the Torrey Pines submarket now anchors the newest phase of One Alexandria Square and is home to Lilly Gateway Labs. New highly impactful amenities enriching the vibrant Megacampus ecosystem and helping tenants attract, retain, and engage top talent include a nutritious grab-and-go café with garden seating, a destination restaurant, large event lawn, high-tech meeting venues, and a restorative walking path. The campus is also proximate to a dense concentration of renowned research institutions, such as the Salk Institute, Sanford Burnham Prebys, Scripps Research, and UC San Diego, positioning One Alexandria Square tenants at a vital nexus of opportunities for collaboration.

Lilly Gateway Labs San Diego opens with a diligently selected cohort of venture-backed biotech companies working across a diverse array of modalities and disease areas, including Alzheimer's, Parkinson's, cardiovascular and metabolic diseases, and oncology. The new site, which is located in a LEED Gold certified all-electric laboratory facility, features modular laboratory spaces with adjacent collaboration areas, scientific amenities like cutting-edge microscopy and sequencing tools, first-class operational support services, strategic programming, and dedicated building security and concierge services. To learn more about Lilly Gateway Labs, visit gatewaylabs.lilly.com.

 

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500^® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus^™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. As of June 30, 2025, Alexandria has a total market capitalization of $25.7 billion and an asset base in North America that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties undergoing construction and one 100% pre-leased committed near-term project expected to commence construction in the next year. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value. For more information on Alexandria, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the potential impact of Lilly Gateway Labs and Alexandria's collaboration on the discovery and development of medicines, novel therapies, and treatments; Lilly's continued ability to collaborate with biotech companies and scientists; benefits available to participants of Gateway Labs; the features and amenities of the Lilly Gateway Labs site in San Diego; and the likelihood of continued commitment and efforts by Alexandria to foster innovation and collaboration. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. 

CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@are.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-strategically-partners-with-lilly-on-newest-lilly-gateway-labs-at-the-one-alexandria-square-megacampus-in-san-diegos-torrey-pines-to-accelerate-the-development-of-life-changing-medicines-302567431.html

SOURCE Alexandria Real Estate Equities, Inc.

FAQ

What is the new Lilly Gateway Labs facility at Alexandria Real Estate's (ARE) San Diego campus?

Lilly Gateway Labs San Diego is a shared innovation hub at ARE's One Alexandria Square Megacampus, designed to help biotech companies develop medicines through access to Lilly's expertise, resources, and venture network.

Where is ARE's new Lilly Gateway Labs located and what amenities does it offer?

The facility is located in Torrey Pines, San Diego, featuring modular laboratories, collaboration areas, microscopy and sequencing tools, plus amenities like a café, restaurant, event lawn, and walking path.

How many therapeutics are currently in development across Lilly Gateway Labs locations?

Over 50 novel therapeutics and platforms are currently in development across Gateway Labs' first three U.S. sites in South San Francisco and Boston.

What types of research will be conducted at ARE's new Lilly Gateway Labs in San Diego?

The facility will host biotech companies researching treatments for Alzheimer's, Parkinson's, cardiovascular and metabolic diseases, and oncology.

How does the ARE-Lilly partnership benefit biotech companies?

Companies benefit from ARE's real estate infrastructure and operations expertise combined with Lilly's scientific expertise, mentorship, and access to venture capital through its network, including Alexandria Venture Investments.